Keywords: Ariad, Merck & Co, Ridaforolimus, Revised collaboration, Sarcoma

Ariad views progress in negotiations with Merck & Co on ridaforolimus

Article | 17 March 2010

Cambridge, Massachusetts-based Ariad says it is engaged in advanced negotiations with US drug giant Merck & Co regarding the terms ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in